赛托瑞医疗 CYTX 深 沪
等待开盘 12-19 09:30:00 美东时间
0.2077
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 总市值 376.46万
- 52周最高 562.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 153.00
- 委 比 0.00%
- 总股本 1812.50万
- 历史最高 554625.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 153.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Plus Therapeutics, Inc. subsidiary CNSide Diagnostics announced the hiring of Prem Gurnani as Senior Director of Lab Operations and Elaine Luckey as Director of Quality & Regulatory Affairs. Both received stock options and RSUs as part of their compensation. The company expects these hires to enhance its capabilities in addressing the CNS cancer diagnostics market.
12-09 12:30
Plus Therapeutics To Present ReSPECT Phase 1 Dose Escalation Study Results For Leptomeningeal Metastases At 2025 SABCS
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
12-01 20:38
Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Humana, Inc. (NYSE:HUM),
11-20 20:34
Plus Therapeutics granted 180-day to regain compliance with Nasdaq
Plus Therapeutics (PSTV) announced on Monday that it has received an additional 180-day extension period from the Nasdaq to regain compliance with the $1.00 minimum bid price requirement as per Nasdaq...
11-17 21:06
Plus Therapeutics Gains Nasdaq Extension for Compliance
Plus Therapeutics ( ($PSTV) ) has provided an announcement. On November 17, 202...
11-17 20:58
HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $2
HC Wainwright & Co. analyst Sean Lee maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $3 to $2.
11-03 19:31
Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 89.19 percent increase over losses of $(0.37) per share from
10-31 04:28
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
10-21 20:28
Plus Therapeutics Signs Lease Agreement in Houston
An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2...
10-21 19:50
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
10-21 19:42
